Vitamin D Supplementation and Metabolism in Vitamin D Deficient Elderly

Not Applicable

Terminated

• Conditions: Vitamin D Deficiency; Metabolic Syndrome
• Interventions: Other: Vitamin D2/3 Repletion + RT; Dietary Supplement: RDA Vitamin D3 only; Other: Vitamin D2/3 Repletion + AEX; Dietary Supplement: Vitamin D2/3 Repletion only

• Registration Number: NCT01145703
• Lead Sponsor: Baltimore VA Medical Center

Brief Summary

The purpose of this study is to examine the effects of Vitamin D supplementation on the reasons (mechanisms) underlying the development of type 2 diabetes, metabolic syndrome (high blood pressure, cholesterol, diabetes, body weight/obesity), muscle weakness and wasting (sarcopenia), and impaired physical function (poor balance and walking) associated with vitamin D deficiency and osteopenia/osteoporosis (bone loss). The investigators obtain vitamin D through our diet and sunlight, and its conversion to active vitamins in the liver and kidneys promotes the intestinal absorption of calcium and regulation of bone growth. Therefore, vitamin D deficiency has been known for years to lead to weakened bones (osteopenia and osteoporosis). However, more recently, studies show vitamin D deficiency is associated with a number of other diseases, including type 2 diabetes, muscle weakness, frailty, and the metabolic syndrome. It has also been associated with cognitive impairment. Diabetes affects multiple organ systems including the heart, kidneys, musculoskeletal and nervous system. The possibility that vitamin D deficiency is linked to the development of type 2 diabetes, metabolic syndrome, muscle weakness and wasting (sarcopenia) and osteopenia/osteoporosis, and that vitamin D supplementation decreases the risk for these diseases, provides a relatively easy/accessible and inexpensive model of preventive therapy to decrease the incidence of these diseases. In addition, it is likely that genetic (inherited) factors play a role, but the relationship of these genes to these metabolic abnormalities have not been elucidated. Understanding the role of Vitamin D in health will allow us to translate these findings into therapy.

Detailed Description

Not available

Study Timeline

• Study Start: 2010-05
• Study First Submitted: 2010-06-16
• Study First Submitted QC: 2010-06-16
• Study First Posted: 2010-06-17
• Primary Completion: 2013-02
• Study Completion: 2013-02
• Status Verified: 2014-09
• Last Update Submitted: 2014-09-04
• Last Update Posted: 2014-09-05

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 39

Inclusion Criteria

• 40-85 years of age
• Women must be post menopausal (absence of menses for 12 months or greater)
• 25-hydroxyvitamin D level below 20 ng/ml (50 nmol/L)
• BMI 25-45 kg/m2
• Non smoker ( non smoking for at least 12 months:cigarettes, cigars, pipes)

Exclusion Criteria

• Symptomatic heart disease, CAD, CHF, or uncontrolled hypertension (BP over 180 mm HG) unless medically stabilized
• Currently being treated for active cancer
• Type 1 diabetes; insulin treatment for diabetes, poorly controlled diabetes, HgA1c >10%
• Allergic to lidocaine
• History of seizures or taking anti-seizure or anti convulsion medications
• Untreated dyslipidemia with National Cholesterol ATPIII 10 year cardiac risk score greater than 10% (www.nhlbi.nih.gov/guidelines/cholesterol/atp3upd04.htm)
• Taking oral steroids, warfarin or other medications interfering with fat/muscle metabolism that may not be safely discontinued temporarily for specific procedures (ie for 72 hours prior)
• Taking medication that interfere with ability to replete Vitamin D
• Abnormal liver function 2 times normal levels
• Abnormal renal function (BUN above 40 mg/dl, Cr above 1.8 mg/dl, CrCl<60mg/dl)
• Hypercalcemia (Ca>10.2mg/dl)
• Anemia HCT below 30 mg/dl, platelets below 100,000/cm3
• Chronic pulmonary disease (on supplemental O2)
• Other systemic disorders that are not medically treated and stable or affect the ability to absorb Vitamin D.
• MMSE below 24, dementia or unstable clinical depression by exam
• Abnormal response to exercise test (ST segment depression greater than 2mm, chest pain, significant arrhythmias, extreme shortness of breath, cyanosis, exercising BP above 240/120 mm HG, or other contraindications to exercise) *requires follow up treatment w/ primary MD for continued participation in study
• Aerobically trained with VO2max greater than 2 SD above age-adjusted mean
• Participant is, in the opinion of the investigator, unable to adhere to the study protocol due to medical or orthopedic conditions that limit ability to exercise or travel to the Baltimore VA for protocol procedures.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: FACTORIAL

Arm && Interventions

Group	Intervention	Description
Vit D repletion + 6M Supplementation +RT	Vitamin D2/3 Repletion + RT	-
RDA Vitamin D	RDA Vitamin D3 only	-
Vit D repletion + 6M Supplementation +AEX	Vitamin D2/3 Repletion + AEX	-
Vit D repletion + 6M Supplementation	Vitamin D2/3 Repletion only	-

Primary Outcome Measures

Name	Time	Method
glucose tolerance and insulin sensitivity	Baseline, 3 months and 6 months

Secondary Outcome Measures

Name	Time	Method
muscle structure, inflammation and metabolic function to cause sarcopenia and frailty	Baseline, 3 months and 6 months
physical performance, balance and strength to increase strength and balance to reduce fall risk in older people	Baseline, 3 months and 6 months
cognitive function	Baseline, 3 months and 6 months

Trial Locations

Locations (1)

Baltimore VAMC; 🇺🇸 Baltimore, Maryland, United States